EW — Stock Film
STOCK FILMSCENE 1/11EW · $89.83
Stock Expert AI presents
EW
Edwards Lifesciences Corporation
~4 min film100% real numbers0 jargon
WHAT DOES THIS COMPANY DO?
Edwards Lifesciences Corporation. A quick introduction.

On the stock market since 2000, it operates in the world of health and science. It has 16,000 employees. Now — the numbers.

on the stock market since 2000
16K employees
$53B market value
Revenue last year:
$0
The net profit left over:
$0
Out of every $100 in sales, $18 stays as net profit.
THE SLICE THAT TURNS INTO PROFIT: 18%

This is an established company with proven profits.

WHERE DOES THE MONEY COME FROM?
74%Transcatheter Heart Valves
Transcatheter Heart Valves 74%Surgical Heart Valve Therapy 17%Transcatheter Mitral and Tricuspid Therapies 9%
74% of all revenue comes from a single line: Transcatheter Heart Valves.

That much dependence is a risk in itself: if this one line weakens, the whole company feels it directly.

Cash on hand:
$0
Total debt:
$0
The cash outweighs the debt.

If every debt were paid off today, $3.5B would still be left in the vault — a solid cushion for hard times.

INSIDE THE REPORT CARD

We compared this company with its own sector across five subjects.

A score of 50 means class average.

BUSINESS QUALITY
91
very strong

Profit power and business quality lead the class.

FINANCIAL STRENGTH
91
very strong

Debt is low and cash is strong; the finances stand solid.

VALUATION
66
strong

Clearly above the class average — a step short of the very top.

GROWTH
88
very strong

This grade is a blend: the profit side is strong, the sales tempo slow.

PRICE MOMENTUM
61
average

The price is looking for direction — no strong breakout, no collapse.

No real weak spot in any of the five subjects — a balanced report card.

THE COUNCIL REVIEW
9

angles, checked one by one.

The 4 that stand out are on screen; the rest came back neutral.

The council scores out of 10; report-card grades are out of 100.

STRENGTHS
Fat profit per sale, but shrinking10/10
A strong cash pile8/10
Few are betting against it10/10
WEAK SPOTS
Executives aren’t buying3/10
WORTH WATCHING

Executive Buying: The trades send no strong signal of confidence.

THE FIVE-YEAR JOURNEY
Below the peak, but no collapse.

The stock trades 31% below its peak. The market has trimmed its expectations for the company.

1
THE BRIGHT SIDE · 1/3
A fat but narrowing margin

The net profit margin is 18% — still a thick cushion, though costs have been eating into it lately.

2
THE BRIGHT SIDE · 2/3
Strong cash, light debt

There is $4.2B in the vault; even if every debt were paid off, $3.5B would remain.

3
THE BRIGHT SIDE · 3/3
Delivers on expectations

It met or beat analyst expectations in 7 of the last 8 quarters — consistency is a promise kept.

1
THE RISKS · 1/2
A rich price tag

The company’s market value is 49 times its annual profit. Even a small disappointment could hit the price hard.

2
THE RISKS · 2/2
Executives aren’t buying

No clear buy-side message is coming from the executive floor. Council score: 3/10.

FINALE · THE GRADE
A
0 / 100 · MoonshotScore

On our five-subject report card, EW sits near the top of the class. A high grade doesn’t mean “guaranteed win” — it means “the evidence looks strong for now.”

The takeaway: EW is an established business that has proven its profits for years. The real debate here isn’t the price — it’s whether the company can keep up this pace.

The total grade weighs these five subjects against the sector — it isn’t a simple average of the five.

What would you like to do next?
Open the stock page →
This was a film — not investment advice.
Data: FMP & company filings
Aug 21, 2026 · stockexpertai.com · Stock Film